Product Release Vetter Dual-Chamber Technology
For complex compounds that require lyophilization, Vetter offers two efficient and user-friendly systems.
Vetter dual-chamber technology
For complex compounds that require lyophilization, Vetter offers two efficient and user-friendly systems: the dual-chamber Vetter Lyo-Ject® syringe and dual-chamber V-LK® cartridge. Lyophilized drug resides in one chamber; diluent in the other. The drug is reconstituted just prior to administration in a few simple steps. Why dual-chamber technology? Simple administration, precise dosing, and increased API yield, due to reduced overfill requirements.
Dosage forms:
In addition to lyophilized-drug/diluent combinations, dual-chamber systems may also be used for liquid/liquid or powder/liquid drug combinations.
Sizes:
Dual-chamber syringe: in 1 ml, 2.5 ml and 5 ml sizes, covering fillvolumes of 0.1 ml - 5 ml per chamber
Dual-chamber cartridge: in 1.5 ml size, covering fill volumes of 0.1 ml - 1.4 ml (first chamber) and 0.1 ml - 1.3 ml (second chamber)
Click here for more information.
For US inquiries please call +1-847-581-6888.
For EU inquiries please call +49-751-3700-0.
info@vetter-pharma.comwww.vetter-pharma.com
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
